Teneligliptin: DPP-4 inhibitor in the treatment of type II Diabetes Mellitus

K. R. Danao, M. V. Shende, R. A. Gupta, N. G. Dumore, U. N. Mahajan


The collective review of teneligliptin as an antidibetic drug concerning about the mechanisms of action, pharmacokinetic study, pharmacodynamic study, toxicological study and dose and its contraindication. Teneligliptin is used in the treatment of type II diabetes mellitus. Teneligliptin, a third generation DPP-4 inhibitor, teneligliptin was approved by the US Food and Drug Administration on 2012 based on a large development program. Teneligliptin, a novel DPP-4 inhibitor, exhibits a unique structure characterized by five consecutive rings, which produce a potent and long-lasting effect. Teneligliptin is currently used in cases showing insufficient improvement in glycemic control even after diet control and exercise or a combination of diet control, exercise, and sulfonylurea or thiazolidine-class drugs. In adults, teneligliptin is orally administered at a dosage of 20 mg once daily, which can be increased up to 40 mg per day. Due to the metabolites of this drug are eliminated via renal and hepatic excretion so, adjustable dose is not required to renal impairment patient. In this review, all the clinical data is described. Teneligliptin shows promise in stabilizing glycemic fluctuations throughout the day and consequently suppressing the progression of diabetic complications.


Teneligliptin, DPP-4 inhibitor, hypoglycemic, toxicity

Full Text:


DOI: https://doi.org/10.7439/ijpp.v7i4.4347


  • There are currently no refbacks.

Copyright (c) 2017 International Journal of Phytopharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.